Arimidex: Compliance and arthralgias in clinical therapy (COMPACT) - COMPACT

Inclusion Criteria

• Inclusion Criteria:
• - Postmenopausal women aged 18 years or older;
• Postmenopause is defined as
• Natural menopause with menses >1 year ago or
• Serum FSH (> 20 IU/ l), and E2 levels in the postmenopausal range or
• patients who had bilateral oophorectomy
• - Histologically / cytologically confirmed primary diagnosis of early breast
• cancer (M0) with hormone sensitive tumour (ER+ve and/or PgR+ve)
• - Patients, who underwent breast cancer surgery and, if appl. radiation therapy
• and/or neo/adjuvant chemotherapy and have taken adjuvant endocrine treatment
• with anastrozole (upfront or following two to three years of tamoxifen) min
• 3 max 6 months
• - In case of a previous therapy with tamoxifen (switch-therapy), duration of
• tamoxifen treatment for at least two and up to three years.
• Exclusion Criteria:
• - Patients with severe renal function disorders (Creatinine clearance < 20
• ml/min or Patients with moderate or severe disorders of hepatic function
• - Concomitant treatment with drugs known to affect sex hormonal status and
• tamoxifen
• - Patients with ductal carcinoma in situ (DCIS) without primary diagnosis of
• early breast cancer (M0)
• - Evidence of any significant clinical disorder or laboratory finding which
• in the opinion of the investigator, makes it undesirable for the patient
• to participate in the program